Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as
motexafin gadolinium may make tumor cells more sensitive to radiation therapy.
PURPOSE: Phase II trial to study the effectiveness of motexafin gadolinium plus radiation
therapy to the brain in treating patients who have newly diagnosed glioblastoma multiforme.